Reuters logo
Osiris rises on nod for wound treatment reimbursement
May 30, 2012 / 2:27 PM / 6 years ago

Osiris rises on nod for wound treatment reimbursement

(Reuters) - Shares of Osiris Therapeutics Inc rose 15 percent on Wednesday, after U.S. health regulators said the stem-cell technology company’s wound treatment was eligible for reimbursement when used in hospitals in out-patient settings or in ambulances.

The Center for Medicare & Medicaid Services also cleared the pathway for a permanent reimbursement code for Grafix, Osiris’s wound-care matrix containing stem cells, on Tuesday.

A permanent code makes reimbursement for the treatment faster and easier, thus increasing the chances of a physician prescribing it.

Osiris said if the permanent reimbursement code for Grafix was approved, it could become effective from January next year.

First-quarter revenue from the company’s biosurgery products - Grafix and a bone matrix product called Ovation - have risen about 50 percent to $1.14 million.

Shares of the Columbia, Maryland-based company were trading up 8 percent at $6.98 Wednesday morning on the Nasdaq. They jumped to $7.49 earlier in the session.

(Reporting by Vidya P L Nathan in Bangalore; Editing by Don Sebastian)

This story was corrected in paragraph 2 to say the regulator was Center for Medicare & Medicaid Services, not the U.S. FDA

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below